Drugs / FTC
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06891066 Comparator | Apr 2025 → Aug 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891066 ↗ |
| Route | Oral | “BIC 50mg oral tablet/FTC 200mg oral tablet/TAF 25 mg oral tablet administered orally” NCT06891066 ↗ |